Entrada Therapeutics (TRDA) Current Leases (2022 - 2026)

Entrada Therapeutics' Current Leases history runs 5 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• On a quarterly basis, Current Leases fell 34.24% year-over-year to $4.3 million in Q1 2026; TTM through Mar 2026 was $4.3 million, a 34.24% decrease from a year earlier, with the FY2025 full-year figure at $4.1 million, down 45.26% from the prior year.
• Current Leases improved to $4.3 million in Q1 2026 per TRDA's latest filing, from $4.1 million in the prior quarter.
• Across five years, Current Leases topped out at $8.6 million in Q2 2024 and bottomed at $4.1 million in Q4 2025.
• The 5-year median for Current Leases is $7.6 million (2024), against an average of $7.0 million.
• Across the five-year window, Current Leases climbed 16.87% in 2024 and tumbled 45.26% in 2025, its largest moves.
• Year by year, Current Leases stood at $8.4 million in 2022, then decreased by 5.91% to $7.9 million in 2023, then decreased by 4.43% to $7.6 million in 2024, then plunged by 45.26% to $4.1 million in 2025, then gained by 3.46% to $4.3 million in 2026.
• Per Business Quant, the three latest TRDA Current Leases figures stand at $4.3 million (Q1 2026), $4.1 million (Q4 2025), and $4.4 million (Q3 2025).